Stay in touch
Prime news from our network.
#read
Merck strengthens next-gen biology portfolio through acquisition of HUB Organoids
Merck has successfully completed the acquisition of HUB Organoids Holding B.V., adding leading organoid development technologies to its portfolio. HUB is an internationally recognised pioneer in the production of organoids, which are highly developed 3D cell culture models that provide precise data on drug efficacy at an early stage.
06/01/2025
This technology enables faster and more efficient development of new therapies and complements Merck's existing range of cell culture media, reagents and laboratory equipment. By integrating HUB's organoid technology with our cell culture expertise, we are creating innovative solutions that can revolutionise the drug discovery process," said Jean-Charles Wirth, Head of the Science and Lab Solutions division at Merck. HUB's portfolio includes basic patents, services such as the development of new models and assays as well as high-throughput screening solutions. The acquisition strengthens Merck's position as a leading partner for academic research, biotechnology and pharmaceutical companies and underscores the company's commitment to differentiated solutions in the life science industry.
The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.